NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION SOLUTION

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE)

Доступно од:

BAXTER CORPORATION

АТЦ код:

C01CA03

INN (Међународно име):

NOREPINEPHRINE

Дозирање:

0.016MG

Фармацеутски облик:

SOLUTION

Састав:

NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE) 0.016MG

Пут администрације:

INTRAVENOUS

Јединице у пакету:

15G/50G

Тип рецептора:

Ethical

Терапеутска област:

ALPHA-AND BETA-ADRENERGIC AGONISTS

Резиме производа:

Active ingredient group (AIG) number: 0131301002; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2020-07-02

Карактеристике производа

_Prescribing Information - Norepinephrine Bitartrate in 5% Dextrose
Injection _
_USP)_
_Page 1 of 13 _
PRESCRIBING INFORMATION
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION
0.016 mg / mL and 0.032 mg / mL norepinephrine
(as norepinephrine
bitartrate)
Sterile Solution
for Intravenous Infusion
Manufacturer Standard
SYMPATHOMIMETIC AMINE FOR USE IN HYPOTENSIVE EMERGENCIES
Baxter Corporation
Date of Revision:
June 24, 2021
Mississauga, Ontario
L5N 0C2
Control No.: 249005
Baxter and VIAFLO are Trademarks of Baxter International Inc.
_Prescribing Information - Norepinephrine Bitartrate in 5% Dextrose
Injection _
_USP)_
_Page 2 of 13 _
DESCRIPTION
Norepinephrine
(sometimes
referred to as _ l-arterenol/Levarterenol or l-norepinephrine) _is a
sympathomimetic
amine which differs from epinephrine by the absence of a methyl group
on the
nitrogen atom.
ACTIONS
Norepinephrine bitartrate functions
as a powerful
peripheral
vasoconstrictor
(alpha-adrenergic
action) and as a potent inotropic
stimulator
of the heart and dilator of coronary
arteries (beta-
adrenergic action). Both of these actions result in an increase in
systemic blood
pressure and
coronary artery blood flow. Cardiac output will vary reflexly in
response to
systemic hypertension
but is usually
increased in hypotensive
man when the blood
pressure is
raised
to an optimal
level.
In myocardial
infarction
accompanied
by
hypotension.
Norepinephrine bitartrate usually
increases aortic blood pressure, coronary artery blood flow, and
myocardial oxygenation,
thereby
helping to limit the area of myocardial ischemia and infarction.
Venous return is
increased and the
heart tends to resume a more normal rate and rhythm than in the
hypotensive
state.
In hypotension
that persists after correction of blood
volume
deficits,
norepinephrine bitartrate
helps raise the
blood pressure to an optimal level and establish a more adequate
circulation.
In _myocardial infarction, _norepinephrine bitartrate has been shown
to increase greatly the patient
survival rate.
Norepinephrine bitartr